Two stories converging on this week's Trade to Black - the Flowhub-presented cannabis business program hosted by Shadd Dales and Anthony Varrell - capture something worth paying attention to: the pharmaceutical and retail sides of cannabis are both maturing fast, and the signals are arriving simultaneously. One guest lays out how CBD prescribing might actually function post-rescheduling. The other brings a quarterly earnings report that reads like a proof of concept for loyalty-driven cannabis retail.
The CBD Question No One Has Cleanly Answered
Pulak Sharma, co-founder and CEO of Kazmira Therapeutics, joins the program to address a deceptively simple question: once cannabis is rescheduled at the federal level, how does CBD coverage, prescribing, and delivery actually work in practice? The emphasis on "actually" matters. Rescheduling has been discussed in broad strokes for years - reduced regulatory friction, expanded research access, potential insurance pathways - but the operational details of integrating cannabinoid-based therapeutics into existing medical infrastructure remain fuzzy at best.
Sharma's perspective is informed by Kazmira's own positioning. The company announced on January 20 the launch of what it describes as the first cannabis-grade dispensary in Colorado, a move that signals ambitions well beyond the typical dispensary model. The term "pharmaceutical-grade" is doing real work here; it implies standardized dosing, quality controls aligned with FDA expectations, and a distribution framework that could, in theory, slot into a post-rescheduling medical system. Whether that system materializes - and how quickly - remains an open question. But real-world medical evidence around cannabinoids is accumulating, and Sharma is expected to walk through what that evidence is starting to clarify.
Here's the catch: rescheduling from Schedule I to Schedule III doesn't automatically create insurance reimbursement pathways or prescribing protocols. Those downstream effects require additional regulatory and commercial infrastructure. The conversation promises to unpack what that build-out might look like.
High Tide Posts What May Be Its Strongest Quarter Ever
Then there's the money side. High Tide Inc. (TSX: HITI | NASDAQ: HITI), the Canadian cannabis retail and e-commerce company led by CEO Raj Grover, just released fourth-quarter and year-end results for fiscal 2025 - and the numbers are hard to ignore.
- Revenue hit a record $164.0 million for the three months ended October 31, 2025, up 19% year over year from $138.3 million - the fastest growth rate in nine quarters.
- Gross profit reached a record $42.5 million for the same period, up 19% year over year and 6% sequentially.
- The company reported positive free cash flow alongside expanding margins.
What makes this interesting beyond the headline figures is the model underneath them. High Tide has built its retail operation around a loyalty and membership program - a structure more common in consumer retail than in cannabis. The operating thesis is straightforward: recurring customers, predictable traffic, better unit economics. That thesis is now showing real operating leverage, which is exactly what public-market investors want to see from a cannabis company still fighting for institutional credibility.
Grover's appearance on the show comes at a moment when Canadian cannabis companies are under pressure to prove they can generate consistent, profitable growth rather than just top-line expansion. A 19% revenue increase paired with margin improvement and positive cash flow is a strong counterargument to the bear case.
Why These Two Stories Belong Together
It's tempting to treat pharmaceutical-grade CBD development and discount-club cannabis retail as separate conversations. They aren't - not really. Both reflect an industry that is, slowly and unevenly, professionalizing. Kazmira is betting that the regulatory environment will eventually reward companies that built to pharmaceutical standards before they were required. High Tide is betting that disciplined retail execution and customer retention matter more than store count. Both bets assume the same thing: that the cannabis industry's next phase will favor operators who built durable infrastructure over those who simply chased volume.
Whether rescheduling arrives on the timeline the market hopes for, or whether Canadian retail consolidation shakes out the way High Tide expects - those are genuinely uncertain. But the fact that both stories are landing in the same news cycle tells you something about where the industry's center of gravity is shifting. Away from hype. Toward operations.
